SCN8A and Lennox-Gastaut syndrome: While an effective dose range for CBD in patients with SCN8A mutations has not yet been established, in a long-term open label trial in patients with DS and Lennox-Gastaut syndrome (GWPCARES, NCT02224573), CBD doses from 2.5 to 20 mg/kg/d were administered.